Gemcitabine

In this video, Laleh Melstrom, MD, MS, discusses results from phase 2 ALPACA study presented at ASCO Gastrointestinal Cancers Symposium.

The FDA approved pembrolizumab in combination with gemcitabine and cisplatin chemotherapy for adults with locally advanced unresectable or metastatic biliary tract cancer.

Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients with locally advanced pancreatic cancer, according to results of the phase 3 TiGeR-PaC study.

CHICAGO — First-line NALIRIFOX significantly extended in OS and PFS vs. gemcitabine and nab-paclitaxel among patients with treatment-naive metastatic pancreatic ductal adenocarcinoma, according to a study presented at ASCO Annual Meeting.

In this video, Daneng Li, MD, a medical oncologist at City of Hope, discussed results from the phase 3 KEYNOTE-966 study, presented at American Association for Cancer Research Annual Meeting.

In this video, Ahmed Kaseb, MD, CMQ, discussed results from the phase 3 KEYNOTE-966 study, presented at American Association for Cancer Research Annual Meeting.

In this video, James Cleary, MD, PhD, a medical oncologist at Dana-Farber Cancer Institute, discussed new developing treatment options for biliary tract cancer presented at American Association for Cancer Research Annual Meeting.

In a video interview with Healio, Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, talked about the NAPOLI 3 trial data presented at ASCO Gastrointestinal Cancers Symposium.

In a video interview, Benjamin Schlechter, MD, talked about a “fascinating, compelling and important study” that looked at liposomal irinotecan injection regimen vs. nab-paclitaxel and gemcitabine in metastatic pancreatic cancer.

CHICAGO — The addition of nimotuzumab to gemcitabine prolonged OS and PFS among patients with KRAS wild-type locally advanced or metastatic pancreatic cancer, according to randomized phase 3 study results presented at ASCO Annual Meeting.